HC Wainwright & Co. Reiterates Buy on Rapport Therapeutics, Maintains $66 Price Target
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsReiterationPrice Target
HC Wainwright & Co. analyst Douglas Tsao reiterates Rapport Therapeutics (NASDAQ:RAPP) with a Buy and maintains $66 price target.
HC Wainwright & Co. analyst Douglas Tsao reiterates Rapport Therapeutics (NASDAQ:RAPP) with a Buy and maintains $66 price target.